These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8478872)

  • 21. [New drugs in the therapy of rheumatoid arthritis].
    Sigidin IaA; Tsvetkova ES; Bunchuk NV
    Sov Med; 1981; (9):94-7. PubMed ID: 7031911
    [No Abstract]   [Full Text] [Related]  

  • 22. [Study of a new anti-inflammatory agent in rheumatoid arthritis (author's transl)].
    Commandre F; Viani JL
    J Belge Rhumatol Med Phys; 1975; 30 Spec no():83-94. PubMed ID: 777000
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of bufexamac for rheumatoid arthritis.
    Rose BS; Isdale IC; Conlon PW
    Curr Ther Res Clin Exp; 1970 Mar; 12(3):150-3. PubMed ID: 4985493
    [No Abstract]   [Full Text] [Related]  

  • 24. [Current trends in pharmacotherapy of rheumatoid arthritis].
    Sigidin IaA; Tsvetkova ES; Bunchuk NV; Murav'ev IuV
    Ter Arkh; 1980; 52(1):78-82. PubMed ID: 6989009
    [No Abstract]   [Full Text] [Related]  

  • 25. [Therapeutic effect of trimethazone in patients with progressive polyarthritis. Preliminary communication].
    Trnavský K; Zbojanová M
    Vnitr Lek; 1969 Sep; 15(9):887-91. PubMed ID: 4898807
    [No Abstract]   [Full Text] [Related]  

  • 26. Composite versus individual measures of disease activity in rheumatoid arthritis.
    Neogi T; Felson DT
    J Rheumatol; 2008 Feb; 35(2):185-7. PubMed ID: 18260160
    [No Abstract]   [Full Text] [Related]  

  • 27. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?
    Felson DT; Anderson JJ; Lange ML; Wells G; LaValley MP
    Arthritis Rheum; 1998 Sep; 41(9):1564-70. PubMed ID: 9751088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Orgotein in the treatment of rheumatoid arthritis.
    Menander-Huber KB
    Eur J Rheumatol Inflamm; 1981; 4(2):201-11. PubMed ID: 7044787
    [No Abstract]   [Full Text] [Related]  

  • 29. Research trends in drug therapy for arthritis.
    Smyth CJ
    Univ Mich Med Cent J; 1968; ():277-80. PubMed ID: 4882551
    [No Abstract]   [Full Text] [Related]  

  • 30. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathophysiology of rheumatoid arthritis: split or lump?
    Boers M
    Arthritis Rheum; 2008 Oct; 58(10):2925-7. PubMed ID: 18821696
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Thabane L
    Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trials in rheumatoid arthritis: choosing the right outcome measures--comment on the article by Felson et al.
    Porter D
    Ann Rheum Dis; 2008 Sep; 67(9):1356. PubMed ID: 18697785
    [No Abstract]   [Full Text] [Related]  

  • 34. Assessing single joints in arthritis clinical trials.
    Giles JT; Mease P; Boers M; Bresnihan B; Conaghan PG; Heald A; Maksymowych WP; Maillefert JF; Simon L; Tsuji W; Wakefield R; Woodworth T; Schumacher HR; Bingham CO
    J Rheumatol; 2007 Mar; 34(3):641-7. PubMed ID: 17343312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pooled outcome measures in arthritis: the pros and cons.
    Roberts RS
    J Rheumatol; 1993 Mar; 20(3):566-7. PubMed ID: 8478875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. American College of Rheumatology criteria for improvement in rheumatoid arthritis should only be calculated from scores that decrease on improvement.
    Boers M; Verhoeven AC; van der Linden S
    Arthritis Rheum; 2001 May; 44(5):1052-5. PubMed ID: 11352236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mefenamic acid.
    Br Med J; 1966 Dec; 2(5528):1506-7. PubMed ID: 5333309
    [No Abstract]   [Full Text] [Related]  

  • 39. Glucocorticoids in rheumatoid arthritis: a senescent research agenda on the brink of rejuvenation?
    Boers M
    Best Pract Res Clin Rheumatol; 2004 Feb; 18(1):21-9. PubMed ID: 15123035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs--results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial.
    Symmons D; Tricker K; Harrison M; Roberts C; Davis M; Dawes P; Hassell A; Knight S; Mulherin D; Scott DL;
    Rheumatology (Oxford); 2006 May; 45(5):558-65. PubMed ID: 16263778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.